Expert Opinion on Drug Discovery
ISSN 1746-0441 · Taylor & Francis · United Kingdom · active 1967–2026
Metrics
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric. Citation rates differ enormously between fields, so compare within a discipline.
Is this the right journal for your paper?
The AI Journal Finder ranks the best-matched journals for your paper’s topic — with tier, open access, citation rate and predatory flags. Free to start.
Indexing & access
Access status: hybrid. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is Expert Opinion on Drug Discovery a predatory journal?
Our screening does not flag Expert Opinion on Drug Discovery. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in Scopus, Web of Science, PubMed, which is a positive signal.
Is Expert Opinion on Drug Discovery indexed in Scopus or Web of Science?
Per our venue index, Expert Opinion on Drug Discovery appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is the impact factor of Expert Opinion on Drug Discovery?
Papers in Expert Opinion on Drug Discovery are cited about 6.1 times each within two years of publication, and Scimago places it in Q1, with an h-index of 111. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.
What Scimago quartile is Expert Opinion on Drug Discovery (Q1, Q2, Q3, or Q4)?
Scimago places Expert Opinion on Drug Discovery in Q1 for its subject category. Quartiles split the journals in a field into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Expert Opinion on Drug Discovery is cited about 6.1 times per paper over two years, with an h-index of 111. A journal is ranked per subject category, so one spanning several fields can sit in different quartiles depending on the category.
What is the Web of Science (JCR) quartile of Expert Opinion on Drug Discovery?
The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Expert Opinion on Drug Discovery. The open equivalent is its Scimago quartile, Q1, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.
Is Expert Opinion on Drug Discovery open access?
Our index records its access status as "hybrid". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.
Ready to submit? Tools for your next paper
Similar venues
- Progress in Energy and Combustion ScienceQ1 · Elsevier BV
- Nature Machine IntelligenceQ1 · Nature Portfolio
- Progress in Aerospace SciencesQ1 · Elsevier BV
- Nature Reviews Drug DiscoveryQ1 · Nature Portfolio
- Formal Aspects of ComputingQ3 · Springer Science+Business Media
- Applied Mechanics ReviewsQ1 · American Society of Mechanical Engineers